Gabapentin Capsule
Product Images NDC 70518-4763

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Gabapentin 300mg 70518 4763 00)

Gabapentin Capsule 300 mg label showing a box quantity of 100 capsules. The packaging highlights the strength 300 mg with capsule color yellow noted. The label includes the NDC number 70518-4763-00 and manufacturer details for RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Gabapentin Capsule 300 mg in a single capsule package, repackaged by RemedyRepack Inc. The label includes storage instructions and manufacturer details from Rising Pharma, Inc., Allendale, NJ. The label indicates the product is prescription only with NDC 70518-4763-01.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure of gabapentin, depicting a cyclohexane ring attached to an amino methyl group and a carboxymethyl group, consistent with the molecular arrangement of the active ingredient gabapentin.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

A line graph depicting mean pain scores over eight weeks for two groups: placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes annotations for a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

A line graph depicting mean pain scores over a 7-week period for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks from baseline to week 7, while the y-axis shows the mean pain score ranging from 0 to 10. The graph is divided into a 3-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in mean pain scores over time for both gabapentin groups compared to placebo.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses across two studies. Study 1 compares PBO and GBP 3600 mg; Study 2 compares PBO, GBP 1800 mg, and GBP 2400 mg, showing higher responder percentages for GBP doses with indicated statistical significance.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot illustrating the percentage difference versus daily dose in milligrams for gabapentin across three studies labeled a, b, and c. The graph shows data points at various daily doses from 600 mg to 1800 mg, with corresponding percentage differences ranging approximately from 7% to 17%. The legend identifies symbols representing each study: Study a (black squares), Study b (gray squares), and Study c (white squares).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.